Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Program Title

Cost-Effective Management of NSAID-Related Cardiovascular and Gastrointestinal Risk: Case Studies and Economic Considerations
Release Date: July-14-06
Credit Expiration Date: July-14-07

Faculty

James M. Scheiman, MD
Professor of Internal Medicine
Division of Gastroenterology
University of Michigan Medical Center
Ann Arbor, MI

A. Mark Fendrick, MD
Professor of Internal Medicine and Health Management & Policy
Division of General Medicine
University of Michigan Medical Center
Co-Editor in Chief, American Journal of Managed Care
Ann Arbor, MI

Credit Hours

1

Medium

Online Presentation

Program Description

This program is the second part of a two-part series based on a live audioconference presentation.

In this program, practical case studies are provided which allow the participant to see how patients with cardiovascular or GI risk factors - or a combination of both - are identified, stratified, and managed on an individual basis. Patients with multiple risk factors who are often on concomitant medications cannot be treated with a single algorithm and require individual assessment of their competing risk factors and polypharmacy. Case studies ranging from mild and uncomplicated to severely high-risk and very complicated will be presented showing how each can be resolved in the most cost-effective, efficacious way. Medications associated with risk (NSAIDs, aspirin, and other antiplatelet medications) and gastroprotective cotherapy (PPIs, prostaglandins) will be discussed on a case-by-case basis.

Program Developer/Facilitator


.

Target Audience

This activity has been designed for Managed Care Medical Directors, Pharmacy Directors, Physicians, and Pharmacists.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Assess risk and provide management options for a variety of patient populations requiring antiinflammatory and/or anti-platelet drug therapy.
  2. Identify economic challenges and develop cost effective management strategies for patients at risk for adverse events related to anti-inflammatory and/or anti-platelet drug therapy.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.

James M. Scheiman, MD discloses that he has received grant/research support from AstraZeneca; is a consultant for AstraZeneca, Merck, Nitromed, McNeil, Novartis, TAP, Pfizer, The GI Company, and Pozen; and is on speakers bureaus for AstraZeneca, TAP, Boheringer Ingelheim and Santarus.

A. Mark Fendrick discloses that he is a consultant, a member of advisory committees, and on speakers bureaus for Merck, AstraZeneca, Merck-Medco, Proctor & Gamble, GlaxoSmithKline, Pfizer, Eli Lilly and Co., TAP Pharmaceuticals, Aventis Pharmaceuticals and Amgen.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in each activity.

AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity has been assigned the Universal Program Number 077-999-06-036-H01 and is acceptable for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE-approved providers.

Participants must submit an evaluation and complete a post-test with a score of 70% or better to receive credit.

Commercial Support Statements

Supported by an educational grant from AstraZeneca.

Instructions

  1. Please turn off all pop-up blockers and click on the "Start Program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  2. The next screen will permit you to check for or download the Flash player required to run this program. Clicking on the "slides" button on this screen will begin the program presentation. Clicking on the "Q and A" button will bring you to the pre-recorded question and answer session. The program, Q and A, post-test and evaluation will take approximately 60 minutes to complete.

  3. Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE certificate.

Certificate Fee

$0.00

Disclaimer

©2006, Medical Communications Media, Inc. All rights reserved.

None of the contents may be reproduced in any form without prior written permission of the publisher. The opinions expressed are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH, Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS